The effects of novel polymeric therapeutics based on water-soluble N-(2-hydroxypropyl)methacrylamide copolymers (P(HPMA)) bearing the anticancer drug doxorubicin (Dox), an inhibitor of ABC transporters, or both, on the viability and the proliferation of the murine monocytic leukemia cell line P388 (parental cell line) and its doxorubicin-resistant subline P388/MDR were studied in vitro. The inhibitor derivatives 5-methyl-4-oxohexanoyl reversin 121 (MeOHe-R121) and 5-methyl-4-oxohexanoyl ritonavir ester (MeOHe-RIT), showing the highest inhibitory activities, were conjugated to the P(HPMA) via the biodegradable pH-sensitive hydrazone bond, and the ability of these conjugates to block the ATP driven P-glycoprotein (P-gp) efflux pump was tested. The P(HPMA) conjugate P-Ahx-NH-N═MeOHe-R121 showed a dose-dependent increase in the ability to sensitize the P388/MDR cells to Dox from 1.5 to 24 μM, and achieved an approximately 50-fold increase in sensitization at 24 μM. The P(HPMA) conjugate P-Ahx-NH-N═MeOHe-RIT showed moderate activity at 6 μM (∼10 times higher sensitization) and increased sensitization by 50-fold at 12 μM. The cytostatic activity of the P(HPMA) conjugate P-Ahx-NH-N═MeOHe-R121(Dox) containing Dox and the P-gp inhibitor MeOHe-R121, both bound via hydrazone bonds to the P(HPMA) carrier, was almost 30 times higher than that of the conjugate P-Ahx-NH-N═Dox toward the P388/MDR cells in vitro. A similar result was observed for P-Ahx-NH-N═MeOHe-RIT(Dox), which exhibited almost 10 times higher cytostatic activity than P-Ahx-NH-N═Dox.

Institute of Macromolecular Chemistry Academy of Sciences of the Czech Republic v v i Heyrovsky Sq 2 162 06 Prague 6 Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc15031975

003      

CZ-PrNML

005      

20151008113826.0

007      

ta

008      

151005s2014 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1021/bm500649q $2 doi

035    __

$a (PubMed)24978588

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Subr, V $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic v.v.i. , Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic.

245    10

$a Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro / $c V. Subr, L. Sivák, E. Koziolová, A. Braunová, M. Pechar, J. Strohalm, M. Kabešová, B. Ríhová, K. Ulbrich, M. Kovář,

520    9_

$a The effects of novel polymeric therapeutics based on water-soluble N-(2-hydroxypropyl)methacrylamide copolymers (P(HPMA)) bearing the anticancer drug doxorubicin (Dox), an inhibitor of ABC transporters, or both, on the viability and the proliferation of the murine monocytic leukemia cell line P388 (parental cell line) and its doxorubicin-resistant subline P388/MDR were studied in vitro. The inhibitor derivatives 5-methyl-4-oxohexanoyl reversin 121 (MeOHe-R121) and 5-methyl-4-oxohexanoyl ritonavir ester (MeOHe-RIT), showing the highest inhibitory activities, were conjugated to the P(HPMA) via the biodegradable pH-sensitive hydrazone bond, and the ability of these conjugates to block the ATP driven P-glycoprotein (P-gp) efflux pump was tested. The P(HPMA) conjugate P-Ahx-NH-N═MeOHe-R121 showed a dose-dependent increase in the ability to sensitize the P388/MDR cells to Dox from 1.5 to 24 μM, and achieved an approximately 50-fold increase in sensitization at 24 μM. The P(HPMA) conjugate P-Ahx-NH-N═MeOHe-RIT showed moderate activity at 6 μM (∼10 times higher sensitization) and increased sensitization by 50-fold at 12 μM. The cytostatic activity of the P(HPMA) conjugate P-Ahx-NH-N═MeOHe-R121(Dox) containing Dox and the P-gp inhibitor MeOHe-R121, both bound via hydrazone bonds to the P(HPMA) carrier, was almost 30 times higher than that of the conjugate P-Ahx-NH-N═Dox toward the P388/MDR cells in vitro. A similar result was observed for P-Ahx-NH-N═MeOHe-RIT(Dox), which exhibited almost 10 times higher cytostatic activity than P-Ahx-NH-N═Dox.

650    _2

$a ABC transportéry $x antagonisté a inhibitory $7 D018528

650    _2

$a akrylamidy $x chemická syntéza $7 D000178

650    _2

$a zvířata $7 D000818

650    _2

$a antibiotika antitumorózní $x farmakologie $7 D000903

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a doxorubicin $x farmakologie $7 D004317

650    _2

$a systémy cílené aplikace léků $7 D016503

650    12

$a chemorezistence $7 D019008

650    _2

$a hydrazony $x chemie $7 D006835

650    _2

$a koncentrace vodíkových iontů $7 D006863

650    _2

$a myši $7 D051379

650    _2

$a P-glykoprotein $x metabolismus $7 D020168

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Sivák, L

700    1_

$a Koziolová, E

700    1_

$a Braunová, A

700    1_

$a Pechar, M

700    1_

$a Strohalm, J

700    1_

$a Kabešová, M

700    1_

$a Ríhová, B

700    1_

$a Ulbrich, K

700    1_

$a Kovář, M

773    0_

$w MED00006456 $t Biomacromolecules $x 1526-4602 $g Roč. 15, č. 8 (2014), s. 3030-43

856    41

$u https://pubmed.ncbi.nlm.nih.gov/24978588 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20151005 $b ABA008

991    __

$a 20151008114012 $b ABA008

999    __

$a ok $b bmc $g 1092851 $s 915101

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2014 $b 15 $c 8 $d 3030-43 $e 20140710 $i 1526-4602 $m Biomacromolecules $n Biomacromolecules $x MED00006456

LZP    __

$a Pubmed-20151005